Shares of the AgeX Therapeutics, Inc. (AGE) stock were rising in the pre-market trading session on Monday, April 26, 2021. AGE stock price saw a surge of 11.97% to reach $1.59 a share as of this writing. AgeX Therapeutics was gaining in the previous trading session and went up by 1.43% having a $1.42 per share price at closing. Let’s try to find the reason behind this bull.
Sometimes nothing is good for everything and the same is the situation for AgeX Therapeutics as we find no recent news by the AgeX Therapeutics, not even in whole April, no analysts upgrades, or upswing targeted per share price of AGE stock to justify the rally. Furthermore, no sympathy play or social media hype is supporting this rally. So, what you need to know at this point? Here is the previous activity by the AgeX stock.
Fourth-quarter and full-year 2020 financial results:
AgeX stock did release its fourth quarter and year 2020 financial results on March 31, 2020, according to which the fourth-year revenue of the AGE stock was recorded $0.5 million while the total revenue of the full year 2020 was $1.9 million as compared to $1.7 million of 2019. Operating expenses for the last three months of 2020 were totaled $2.9 million while these were $12.4 million, higher than the $10.4 million in 2019.R&D expenses reduced to $5.0 million in 2020 as compared to $5.9 million in 2019. General and Administrative expenses for the AGE stock were decreased to $7.4 million in 2020 from $8.1 million in 2019.
At the end of 2020, AGE stock had cash, cash equivalents, and restricted cash of $0.6 million as compared to $2.5 at the end of the prior year. Loans from Juvenescence, disposition LifeMap Sciences, Inc, a subsidiary of AgeX, and offering of shares of AgeX common stock resulted in net proceeds of $3.2 million as of January 1, 2021.
Though the AGE stock is hot among investors so far, we don’t find any specific news related to it to justify the bullish sentiment. AgeX recent financial results show that the AGE stock has shown growth over time but still, deep analysis of its balance sheet, fundamentals, and future growth is necessary before adding this stock to the portfolio.